首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2028篇
  免费   194篇
  国内免费   29篇
耳鼻咽喉   7篇
儿科学   153篇
妇产科学   38篇
基础医学   326篇
口腔科学   105篇
临床医学   206篇
内科学   341篇
皮肤病学   55篇
神经病学   58篇
特种医学   190篇
外科学   295篇
综合类   57篇
一般理论   1篇
预防医学   141篇
眼科学   84篇
药学   82篇
中国医学   6篇
肿瘤学   106篇
  2023年   16篇
  2022年   26篇
  2021年   29篇
  2020年   24篇
  2019年   19篇
  2018年   63篇
  2017年   57篇
  2016年   53篇
  2015年   75篇
  2014年   98篇
  2013年   134篇
  2012年   79篇
  2011年   70篇
  2010年   90篇
  2009年   123篇
  2008年   57篇
  2007年   86篇
  2006年   67篇
  2005年   57篇
  2004年   55篇
  2003年   41篇
  2002年   55篇
  2001年   18篇
  2000年   21篇
  1999年   35篇
  1998年   103篇
  1997年   88篇
  1996年   101篇
  1995年   66篇
  1994年   75篇
  1993年   39篇
  1992年   16篇
  1991年   27篇
  1990年   15篇
  1989年   35篇
  1988年   32篇
  1987年   28篇
  1986年   26篇
  1985年   25篇
  1984年   12篇
  1983年   9篇
  1982年   20篇
  1981年   15篇
  1980年   17篇
  1979年   6篇
  1978年   8篇
  1977年   9篇
  1976年   13篇
  1975年   9篇
  1969年   2篇
排序方式: 共有2251条查询结果,搜索用时 15 毫秒
41.
42.
BACKGROUND: Patent foramen ovale (PFO) with or without atrial septal aneurysm (ASA) is highly associated with cerebral ischemic events in young patients. The prevalence of PFO and ASA in elderly patients with cerebral ischemic events is not well described. OBJECTIVE: Our study is to evaluate the frequencies of PFO with right-to-left shunt (RLS) and ASA in elderly patients and to determine whether age is a predictor of flow-reversed PFO with RLS in cerebral ischemic events. METHODS: A prospective registry for all consecutive patients with cerebral ischemic events who were evaluated by transesophageal echocardiography (TEE) for the detection of possible cardiac source of embolization was established and maintained in a university hospital. Patients' demographics including age, gender, ethnic origin, cerebrovascular risk factors, and all positive TEE data were collected from July 2000 to August 2001 for statistical analysis. A univariate and multivariate stepwise logistic regression analysis was performed. RESULTS: In older patients the prevalence of PFO with RLS, PFO, and ASA was 25/118 (20%), 28/118 (24%), and 38/118 (32%), respectively, as opposed to younger patients, in whom it was 35/119 (30%), 39/119 (33%), and 38/119 (32%), respectively. Older patients had higher frequencies of hypertension (59; 69%), CAD (25; 21%), and prior history of stroke (23; 20%) as opposed to younger patients. Younger age (<60 years), gender, smoking history, hypertension, hyperlipidemia, CAD, and prior history of stroke were not associated with higher prevalence of PFO with RLS. Patent foramen ovale was associated with ASA (P < 0.001) and LVH (P < 0.019) in patients with TIA and stroke. In multivariate analysis only ASA (P < 0.001) remained significant with PFO, with RLS controlling for age, gender, and LVH. CONCLUSIONS: PFO with RLS and ASA are frequently present in elderly stroke and/or TIA patients and age is not a predictor for PFO. Transesophageal echocardiography should be considered for all stroke and/or TIA patients irrespective of their age.  相似文献   
43.
44.
45.
In two previous studies, we observed that recombinant human interleukin- 3 (IL-3) induced an increase in marrow burst-forming unit-erythroid- derived colonies in vitro in some patients with Diamond-Blackfan anemia (DBA). To determine whether a similar erythropoietic response could be induced in vivo, we treated 13 patients with DBA (aged 4 to 19 years) with two preparations of IL-3. All patients had absent absolute reticulocyte counts and markedly reduced to absent recognizable bone marrow erythroid elements; patients with circulating reticulocytes in the previous 12 months were excluded from study. All patients except 1 had failed steroid therapy and had been transfusion-dependent since infancy; 1 patient was maintained on high-dose prednisone at the time of enrollment. On the first arm of the study, IL-3 (Immunex Corp, Seattle, WA) was administered subcutaneously using a dose escalation regimen of 125 to 500 micrograms/m2/day in divided dosage at 12-hour intervals, coadministered with 1.5 mg/kg/d of oral ferrous sulphate. Of the 13 patients that entered the trial, 4 stopped prematurely because of adverse side effects. In the other 9 evaluable cases, reticulocytes increased transiently in 1 patient from 0 to 65 x 10(9)/L after 35 days of IL-3 therapy at 250 micrograms/m2, but transfusion dependency persisted. One transient peak in absolute reticulocyte count was noted in 6 other patients, but no erythroid response was observed after completion of a full course of IL-3. Oral prednisone at 0.5 mg/kg/d was then coadministered with IL-3 at 500 micrograms/m2 to 5 of the patients without effect, and treatment was stopped. In 2 patients, a second preparation of IL-3 (Sandoz Canada Inc, Dorval, Quebec, Canada) was initiated in a dose escalation regimen of 2.5 to 10 micrograms/kg and was coadministered with ferrous sulphate. No erythroid response was observed in either patient, and in one of the two, alternate-day subcutaneous recombinant erythropoietin at 300 U/kg was administered for 3 weeks in combination with daily IL-3 at 10 micrograms/kg, but no increased erythropoiesis was seen. Significant increases in white blood cell and eosinophil counts during administration of both preparations of IL-3 were observed in all patients. These data show that the response of DBA patients to IL-3 in vivo is heterogeneous and cannot be predicted from in vitro studies. The absence of a corrective effect of IL-3 in these patients with DBA indicates that a deficiency of the cytokine is not central in the pathogenesis of the disorder.  相似文献   
46.
BACKGROUNDThere has been an increase in cases of inflammatory bowel disease (IBD) in recent years. There is also greater access and availability of immunosuppressive and biological agents, which increase the risk of opportunistic infection despite improving the quality of life and promoting mucosal healing. Tuberculosis (TB) remains a public health problem, and it has a high incidence in several countries. Therefore, knowledge of the risk of developing TB in patients with IBD is important.AIMTo evaluate the risk of active TB in patients with IBD under treatment from an endemic area in Latin America.METHODSA standard questionnaire included demographic variables, clinical aspects of IBD disease, history of active TB during treatment, active TB characteristics and evolution, initial screening and results and time from the start of anti-tumor necrosis factor alpha (TNFα) to TB development.RESULTSAzathioprine, anti-TNFα and the combination of these two drugs were associated with a higher risk of active TB incidence. The TNFα blockers increased the relative risk of developing active TB compared to other treatments. All four multivariable models showed that the use of TNFα blockers alone or in combination with azathioprine was an important risk factor for the incidence of active TB. After adjustment for sex, age, type of IBD and latent TB, anti-TNFα with azathioprine increased the relative risk to 17.8 times more than conventional treatment. Late TB, which was diagnosed 3 mo after the start of anti-TNFα, was the most frequent.CONCLUSIONTreatment with anti-TNFα increased the risk of active TB in IBD patients from an endemic area in Latin America. This risk was increased when anti-TNFα was combined with azathioprine. The time from the beginning of the treatment to the active TB diagnosis suggests a new TB infection.  相似文献   
47.
Abstract: The prevalence of Parkinson’s disease (PD) is expected to double over the next 20 years owing to the increase in life expectancy. This progressive disease has several implications relating to oral health, and many are manageable with proper awareness and knowledge about the disease. This article reviews the epidemiology, pathophysiology, and characteristics of PD, as well as the treatments and oral health considerations to enable dental hygienists to undertake an informed approach to patient management strategies and provide optimal care.  相似文献   
48.
In this research paper, the equilibrium isotherms for the adsorption of cobalt(ii)nitrate and cobalt(ii)chloride on tetrakis(4-tolylphenyl)porphyrin (H2TTPP) were obtained at four temperatures for modeling analysis. The experimental data describing the adsorbed quantity of cobalt particles were measured using the quartz crystal microbalance (QCM) strategy. Then, statistical physics formalism was employed to interpret the complexation mechanism by applying the real gas law that contemplates the interaction between the adsorbate particles in the free state. Advanced models treated with the law of van der Waals were applied for the single and L.B.L adsorptions of Co2+ at various temperatures (288–318 K). The experimental adsorption data of CoCl2 on porphyrins were satisfactorily fitted with the monolayer equation, showing that the chlorine particles had no effect on the complexation system, while the nitrate particles were involved in the adsorption of Co(NO3)2 and contributed to the layer formation. The physicochemical parameters of statistical physics models were estimated and used to compare the complexation mechanisms of both adsorbates. The study of the cohesion pressure (a) and the co-volume (b) confirmed that cobalt chloride guaranteed more stability during the formation of the vitamin B12 nucleus. Deeper energetic analysis demonstrated that cobalt ions were complexed by ionic or covalent bonds in the case of cobalt chloride (complexation energy (–E1/2) varies from −48.2 to −50.3), while a physisorption process took place in the case of cobalt nitrate ((–E1) varies from −33.6 to −36.1), thus indicating that CoCl2–H2TTPP was the most stable complex. The statistical physics models were also used to investigate two thermodynamic functions that govern the adsorption mechanisms, namely, the configurational entropy and the Gibbs free enthalpy.

Quartz Crystal Microbalance (QCM) setup for the measurement of adsorption isotherms of cobalt(ii)nitrate and cobalt(ii)chloride on tetrakis(4-tolylphenyl)porphyrin (H2TTPP).  相似文献   
49.
50.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号